Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 132234 | Registry Identifier | JAPIC-CTI |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate the effects of anacetrapib (MK-0859) on low-density lipoprotein-cholesterol (LDL-C) when compared to placebo in Japanese participants with heterozygous familial hypercholesterolemia when added to an existing statin lipid-modifying therapy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Anacetrapib | Experimental | Participants will receive 100-mg anacetrapib tablet, orally, once-daily for 12 weeks. |
|
| Placebo | Placebo Comparator | Participants will receive placebo tablet, orally, once daily for 12 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anacetrapib | Drug |
|
| |
| Placebo for anacetrapib |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change from Baseline in LDL-C (beta-quantification [BQ] method) | Baseline and Week 12 | |
| Percentage of Participants who Experience at Least One Adverse Event (AE) | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change from Baseline in High-density Lipoprotein-cholesterol (HDL-C) | Baseline and Week 12 | |
| Percent Change from Baseline in Non-HDL-C | Baseline and Week 12 | |
Not provided
Inclusion Criteria:
stable dose of statin± other lipid-lowering medication(s) for at least 6 weeks
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27131642 | Result | Arai H, Teramoto T, Daida H, Ikewaki K, Maeda Y, Nakagomi M, Shirakawa M, Kakikawa T, Numaguchi H, Johnson-Levonas AO, Vaidya S, Blaustein RO. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2016 Jun;249:215-23. doi: 10.1016/j.atherosclerosis.2016.03.017. Epub 2016 Mar 25. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| Percent Change from Baseline in Apolipoprotein A-I (Apo-A-I) |
| Baseline and Week 12 |
| Percent Change from Baseline in Apolipoprotein B (Apo-B) | Baseline and Week 12 |
| Percent Change from Baseline in Lipoprotein(a) (Lp[a]) | Baseline and Week 12 |
| ID | Term |
|---|---|
| C530884 | anacetrapib |
Not provided
Not provided
Not provided